PL2373681T3 - Kompozycje farmaceutyczne albiglutydu - Google Patents
Kompozycje farmaceutyczne albiglutyduInfo
- Publication number
- PL2373681T3 PL2373681T3 PL09832522T PL09832522T PL2373681T3 PL 2373681 T3 PL2373681 T3 PL 2373681T3 PL 09832522 T PL09832522 T PL 09832522T PL 09832522 T PL09832522 T PL 09832522T PL 2373681 T3 PL2373681 T3 PL 2373681T3
- Authority
- PL
- Poland
- Prior art keywords
- albiglutide
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12122908P | 2008-12-10 | 2008-12-10 | |
US15090909P | 2009-02-09 | 2009-02-09 | |
US16399509P | 2009-03-27 | 2009-03-27 | |
US23872309P | 2009-09-01 | 2009-09-01 | |
EP09832522.8A EP2373681B1 (en) | 2008-12-10 | 2009-12-10 | Pharmaceutical compositions of albiglutide |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2373681T3 true PL2373681T3 (pl) | 2017-07-31 |
Family
ID=42243062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09832522T PL2373681T3 (pl) | 2008-12-10 | 2009-12-10 | Kompozycje farmaceutyczne albiglutydu |
Country Status (13)
Country | Link |
---|---|
US (3) | US8748377B2 (pl) |
EP (1) | EP2373681B1 (pl) |
JP (1) | JP2012511586A (pl) |
CY (1) | CY1118731T1 (pl) |
DK (1) | DK2373681T3 (pl) |
ES (1) | ES2620610T3 (pl) |
HR (1) | HRP20170478T1 (pl) |
HU (1) | HUE031900T2 (pl) |
LT (1) | LT2373681T (pl) |
PL (1) | PL2373681T3 (pl) |
PT (1) | PT2373681T (pl) |
SI (1) | SI2373681T1 (pl) |
WO (1) | WO2010068735A1 (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE031900T2 (en) | 2008-12-10 | 2017-08-28 | Glaxosmithkline Llc | Pharmaceutical compositions containing Albiglutide |
WO2011140176A1 (en) | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
MX366405B (es) | 2012-07-01 | 2019-07-08 | Novo Nordisk As | Uso de peptidos glp-1 de accion prolongada. |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
ES2688367T3 (es) | 2012-12-21 | 2018-11-02 | Sanofi | Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
TWI638831B (zh) | 2013-05-28 | 2018-10-21 | 日商武田藥品工業股份有限公司 | 胜肽化合物 |
US20140378374A1 (en) * | 2013-06-21 | 2014-12-25 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treatment |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
BR112016030588A2 (pt) * | 2014-06-25 | 2017-10-31 | Glaxosmithkline Llc | composições farmacêuticas |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
EP3684793A1 (en) | 2017-09-22 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Glucagon-like peptide 1 receptor agonists and uses thereof |
WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
DE69129226T2 (de) * | 1990-01-24 | 1998-07-30 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
CA2262647C (en) | 1996-08-08 | 2007-12-04 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
US7259136B2 (en) | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
US6329336B1 (en) | 1999-05-17 | 2001-12-11 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
CN1462191B (zh) | 2000-05-19 | 2013-07-24 | 埃米林药品公司 | Glp-1用于制备治疗急性冠脉综合征的药物的用途 |
IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
CA2395165C (en) | 2000-10-20 | 2012-05-22 | Mario Ehlers | Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide |
WO2002046227A2 (en) | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
AU2002239384B2 (en) | 2000-12-13 | 2007-01-11 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
KR20040054729A (ko) | 2001-10-18 | 2004-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도 |
AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2003200839B2 (en) | 2002-01-08 | 2008-12-11 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
AU2003226913A1 (en) | 2002-04-04 | 2003-10-20 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
WO2004056313A2 (en) | 2002-12-17 | 2004-07-08 | Amylin Pharmaceuticals, Inc. | Prevention and treatment of cardiac arrhythmias |
US7790681B2 (en) | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
MXPA06009072A (es) | 2004-02-09 | 2007-03-29 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
CN1950078A (zh) | 2004-06-11 | 2007-04-18 | 诺和诺德公司 | 使用glp-1激动剂抵抗药物诱发的肥胖 |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
EA200701362A1 (ru) | 2004-12-22 | 2008-08-29 | Сентокор, Инк. | Агонисты glp-1, композиции, способы и применения |
WO2006073890A2 (en) | 2004-12-24 | 2006-07-13 | Amylin Pharmaceuticals, Inc. | Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis |
JP5114381B2 (ja) | 2005-03-31 | 2013-01-09 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 精神疾患および障害治療用アミリンおよびアミリンアゴニスト |
ES2365410T3 (es) * | 2005-04-08 | 2011-10-04 | Amylin Pharmaceuticals, Inc. | Formulaciones farmacéuticas que comprenden péptido de incretina y un disolvente polar aprótico. |
DK1888103T3 (da) | 2005-04-11 | 2012-04-23 | Amylin Pharmaceuticals Inc | Anvendelse af glp-1, exendin og agonister deraf til forsinkelse eller forhindring af kardial remodellering |
JP2009514900A (ja) * | 2005-11-04 | 2009-04-09 | スミスクライン・ビーチャム・コーポレイション | 血糖降下剤の投与方法 |
BRPI0712559A2 (pt) | 2006-05-26 | 2012-11-20 | Amylin Pharmaceuticals Inc | composiÇÕes e mÉtodos para o tratamento de insuficiÊncia cardÍaca congestiva |
WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
EP2049567A2 (en) | 2006-07-18 | 2009-04-22 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
US20090209469A1 (en) | 2006-08-04 | 2009-08-20 | Dennis Kim | Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition |
PE20080840A1 (es) * | 2006-09-13 | 2008-08-27 | Smithkline Beecham Corp | Metodos para administrar agentes hipoglucemiantes de larga duracion |
EP2163243A1 (en) | 2008-09-12 | 2010-03-17 | Biocompatibles UK Limited | Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof |
HUE031900T2 (en) | 2008-12-10 | 2017-08-28 | Glaxosmithkline Llc | Pharmaceutical compositions containing Albiglutide |
-
2009
- 2009-12-10 HU HUE09832522A patent/HUE031900T2/en unknown
- 2009-12-10 LT LTEP09832522.8T patent/LT2373681T/lt unknown
- 2009-12-10 SI SI200931639A patent/SI2373681T1/sl unknown
- 2009-12-10 JP JP2011540882A patent/JP2012511586A/ja active Pending
- 2009-12-10 PT PT98325228T patent/PT2373681T/pt unknown
- 2009-12-10 PL PL09832522T patent/PL2373681T3/pl unknown
- 2009-12-10 DK DK09832522.8T patent/DK2373681T3/en active
- 2009-12-10 EP EP09832522.8A patent/EP2373681B1/en active Active
- 2009-12-10 US US13/133,976 patent/US8748377B2/en not_active Expired - Fee Related
- 2009-12-10 WO PCT/US2009/067469 patent/WO2010068735A1/en active Application Filing
- 2009-12-10 ES ES09832522.8T patent/ES2620610T3/es active Active
-
2014
- 2014-04-25 US US14/261,641 patent/US20140228284A1/en not_active Abandoned
- 2014-04-25 US US14/261,602 patent/US20140228288A1/en not_active Abandoned
-
2017
- 2017-03-16 CY CY20171100337T patent/CY1118731T1/el unknown
- 2017-03-21 HR HRP20170478TT patent/HRP20170478T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20170478T1 (hr) | 2017-05-19 |
US8748377B2 (en) | 2014-06-10 |
HUE031900T2 (en) | 2017-08-28 |
EP2373681A4 (en) | 2013-11-06 |
US20110301080A1 (en) | 2011-12-08 |
DK2373681T3 (en) | 2017-04-24 |
US20140228284A1 (en) | 2014-08-14 |
JP2012511586A (ja) | 2012-05-24 |
EP2373681B1 (en) | 2017-01-18 |
ES2620610T3 (es) | 2017-06-29 |
EP2373681A1 (en) | 2011-10-12 |
LT2373681T (lt) | 2017-04-10 |
PT2373681T (pt) | 2017-04-11 |
US20140228288A1 (en) | 2014-08-14 |
CY1118731T1 (el) | 2017-07-12 |
SI2373681T1 (sl) | 2017-05-31 |
WO2010068735A1 (en) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2373681T3 (pl) | Kompozycje farmaceutyczne albiglutydu | |
EP2240022A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
GB0814695D0 (en) | Pharmaceutical compositions | |
IL228817A0 (en) | Pharmaceutical compounds | |
PL2323623T3 (pl) | Kompozycje farmaceutyczne | |
EP2271347A4 (en) | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS | |
EP2341773A4 (en) | PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN | |
ZA201102715B (en) | Solid pharmaceutical composition | |
IL208387A0 (en) | Pharmaceutical composition | |
ZA201104670B (en) | Pharmaceutical composition comprising aleglitazar | |
ZA201100871B (en) | Solid pharmaceutical composition | |
EP2296687A4 (en) | PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN DOPAMINE CONJUGATES | |
ZA201006224B (en) | Pharmaceutical composition | |
EP2327406A4 (en) | STABILIZED PHARMACEUTICAL COMPOSITION | |
ZA201101053B (en) | Pharmaceutical compositions of samatotrophic hormones | |
GB2464200B (en) | Pharmaceutical composition | |
IL206487A0 (en) | Pharmaceutical compositions | |
GB0817969D0 (en) | Pharmaceutical composition | |
HK1182939A1 (en) | Stable pharmaceutical composition | |
GB0800659D0 (en) | Pharmaceutical Compositions | |
GB0805807D0 (en) | Novel pharmaceutical compositions | |
GB0804485D0 (en) | Novel pharmaceutical compositions | |
GB0802024D0 (en) | Pharmaceutical compositions | |
GB0806283D0 (en) | Pharmaceutical compositions | |
GB0806156D0 (en) | Pharmaceutical compositions |